GANX - Gain Therapeutics Inc

GANX - Gain Therapeutics Inc

https://gaintherapeutics.com

Recent News

Powered by Alpha Vantage

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - Gain Therapeutics ( NASDAQ:GANX )

Benzinga • 1 month, 3 weeks ago • score: 0.24

BETHESDA, Md., July 24, 2025 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc.

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

GlobeNewswire • 1 month, 3 weeks ago • score: 0.25

BETHESDA, Md., July 24, 2025 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc. ( Nasdaq: GANX ) ( "Gain", or the "Company" ) , a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule therapies, today announced that the ...

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - Gain Therapeutics ( NASDAQ:GANX )

Benzinga • 3 months, 2 weeks ago • score: 0.29

BETHESDA, Md., May 29, 2025 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc. GANX ( "Gain", or the "Company" ) , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the ...

Gain Therapeutics to Participate at The Citizens Life Sciences Conference - Gain Therapeutics ( NASDAQ:GANX )

Benzinga • 4 months, 2 weeks ago • score: 0.31

BETHESDA, Md., May 01, 2025 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is headquartered in Bethesda, Maryland.

52W High

$3.19

52W Low

$1.00

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.14

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.55

EV/Revenue (<3 favorable)

138.33

P/S (TTM) (<3 favorable)

255.50

P/B (<3 favorable)

17.12

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

3.64%

Institutions (25–75% balanced)

10.56%

Shares Outstanding

35,948,600

Float

34,556,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-8,722,057

EPS (TTM)

-0.59

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-2.40%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—